Abstract:Breast cancer is one of the major impediments affecting women globally. The ATP-dependant heat shock protein 90 (Hsp90) forms the central component of molecular chaperone machinery that predominantly governs the folding of newly synthesized peptides and their conformational maturation. It regulates the stability and function of numerous client proteins that are frequently upregulated and/or mutated in cancer cells, therefore, making Hsp90 inhibition a promising therapeutic strategy for the development of new efficacious drugs to treat breast cancer. In the present in silico investigation, a structure-based pharmacophore model was generated with hydrogen bond donor, hydrogen bond acceptor and hydrophobic features complementary to crucial residues Ala55, Lys58, Asp93, Ile96, Met98 and Thr184 directed at inhibiting the ATP-binding activity of Hsp90. Subsequently, the phytochemical dataset of 3210 natural compounds was screened to retrieve the prospective inhibitors after rigorous validation of the model pharmacophore. The retrieved 135 phytocompounds were further filtered by drug-likeness parameters including Lipinski's rule of five and ADMET properties, then investigated via molecular docking-based scoring. Molecular interactions were assessed using Genetic Optimisation for Ligand Docking program for 95 drug-like natural compounds against Hsp90 along with two clinical drugs as reference compounds - Geldanamycin and Radicicol. Docking studies revealed three phytochemicals are better than the investigated clinical drugs. The reference and hit compounds with dock scores of 48.27 (Geldanamycin), 40.90 (Radicicol), 73.04 (Hit1), 72.92 (Hit2) and 68.12 (Hit3) were further validated for their binding stability through molecular dynamics simulations. We propose that the non-macrocyclic scaffolds of three identified phytochemicals might aid in the development of novel therapeutic candidates against Hsp90-driven cancers.

Synthesis and Preliminary Antitumor Activity Evaluation of 17-(5-(substituted Cinnamamido)pentylamino)-17-demethoxygeldanamycin Derivatives As Potent Hsp90 Inhibitors

Synthesis and evaluation of the antitumor activity of 2-amino-4-tetrahydroindazole-substituted benzamide derivatives as HSP90 inhibitors

17-DMCHAG, a New Geldanamycin Derivative, Inhibits Prostate Cancer Cells Through Hsp90 Inhibition and Survivin Downregulation

Potent Hsp90 Inhibitors with Significant Potential in Cancer Therapy

17-Abag, A Novel Geldanamycin Derivative, Inhibits Lncap-Cell Proliferation Through Heat Shock Protein 90 Inhibition

Synthesis and Biological Evaluation of Novel Spin Labeled 18Β-Glycyrrhetinic Acid Derivatives

Design, synthesis and biological evaluation of a new class of Hsp90 inhibitors vibsanin C derivatives

Synthesis and Antiviral and Antitumor Activities of Novel 18β-Glycyrrhetinic Acid Derivatives

Discovery of Potent N-(isoxazol-5-yl)amides As HSP90 Inhibitors.

Design, Preparation and Studies Regarding Cytotoxic Properties of Glycyrrhetinic Acid Derivatives.

Design, Synthesis and Pharmacological Evaluation of 4,5-Diarylisoxazols Bearing Amino Acid Residues Within the 3-Amido Motif As Potent Heat Shock Protein 90 (hsp90) Inhibitors

Synthesis of C3′‐Foused Aryl/Penta‐1,4‐dien‐3‐one/Amine Hybrids as HSP90 C‐Terminal Inhibitors

Geldanamycin, a Heat Shock Protein 90‐binding Agent, Disrupts Stat5 Activation in IL‐2‐stimulated Cells

Design, Synthesis and Anti-cancer Evaluation of Nitrogen-containing Derivatives of 30-Carboxyl of Gambogic Acid

HSP27 Expression Levels Are Associated with the Sensitivity of Hepatocellular Carcinoma Cells to 17-Allylamino-17-demethoxygeldanamycin.

In Vivo and in Vitro Antitumor Activity of 17-Allylamino-17-demethoxygeldanamycin

Probing some recent natural compounds from Phellinus baumii, Colletotrichum sp. and Ligustrum lucidum as heat shock protein 90 inhibitors

Inhibitors of the HSP90 Molecular Chaperone: Current Status

Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies

Fungal mycotoxin penisuloxazin A, a novel C-terminal Hsp90 inhibitor and characteristics of its analogues on Hsp90 function related to binding sites

Geldanamycin, a Naturally Occurring Inhibitor of Hsp90 and a Lead Compound for Medicinal Chemistry